Hope on the Horizon: Australian Scientists Discover Potential Breakthrough in Sepsis Treatment
Sepsis, a life-threatening condition triggered by the body’s overwhelming response to infection, claims the lives of millions globally each year. Now, a team of researchers in Australia has identified a naturally occurring protein that could dramatically improve survival rates – offering a potential new therapy after decades of limited progress.
The Promise of Corticosteroid-Binding Globulin (CBG)
The groundbreaking study, published in Endocrinology and conducted by Adelaide University and the Central Adelaide Local Health Network, centers around corticosteroid-binding globulin (CBG). This protein, produced in the liver, plays a role in transporting the stress hormone cortisol. Researchers discovered that restoring depleted levels of CBG in an animal model of septic shock reduced mortality by over 70 percent.
“The results from our preclinical study were remarkable and demonstrate our therapy has the potential to reduce sepsis-related deaths significantly,” stated Dr. Stewart Ramsay, a Research Fellow from Adelaide University’s School of Medicine.
Understanding Sepsis and the Current Treatment Landscape
Sepsis arises when the immune system’s response to an infection spirals out of control, causing widespread inflammation and potential organ failure. Septic shock, the most severe form, leads to a dangerous drop in blood pressure and can be fatal. Currently, treatment primarily focuses on early antibiotic administration and infection source control. However, there have been no new septic shock therapies introduced into clinical practice for decades.
Professor David Torpy, a Professor of Medicine at Adelaide University and Head of the Royal Adelaide Hospital’s Endocrine and Metabolic Unit, emphasized the urgent need for new treatments. “Despite the high mortality rate, the treatments that we do have come with limited success.”
How CBG Works: Beyond Hormone Transport
For over 13 years, the Adelaide research group has investigated CBG, finding a strong link between its deficiency and the severity of critical illness. They’ve observed that low CBG levels are associated with a threefold increase in the risk of death among intensive care patients with septic shock at the Royal Adelaide Hospital.
Interestingly, the study suggests CBG’s protective effects extend beyond its known function in hormone transport. Researchers believe it triggers an anti-inflammatory response, potentially making it the first new, natural anti-inflammatory discovered in more than half a century. Associate Professor Richard Young, a Senior Research Fellow at Adelaide University and SAHMRI, noted the marked protection against sepsis progression, including significant reductions in hypotension and organ damage observed in the preclinical study.
From Bench to Bedside: Clinical Trials on the Horizon
The research team is now preparing for first-in-human clinical trials, with CBG already in production. Dr. Jessica Lee, the commercialisation manager for the project at AusHealth, is collaborating on this crucial step. Researchers are also hopeful that the therapy could benefit patients with severe burn injuries and other conditions where CBG levels are depleted.
Did you know? Sepsis affects more than 20 percent of global deaths, making it a major international health priority according to the World Health Organization.
Future Trends in Sepsis Research
The CBG discovery highlights a growing trend in sepsis research: focusing on modulating the immune system rather than solely targeting the infection itself. This approach acknowledges the complex interplay between the immune response and organ damage in sepsis.
Other promising areas of investigation include:
- Personalized Medicine: Identifying biomarkers to predict which patients are most likely to benefit from specific therapies.
- Early Detection: Developing rapid diagnostic tools to identify sepsis in its early stages, when treatment is most effective.
- Immunotherapies: Exploring novel immunotherapies to dampen the excessive inflammatory response without compromising the body’s ability to fight infection.
The recent research at the Royal Adelaide Hospital involving a mega-dose of vitamin C (equivalent to 5000 oranges) also demonstrates the ongoing exploration of alternative therapies. While this research is separate from the CBG study, it underscores the commitment to finding innovative solutions for sepsis.
FAQ
Q: What is sepsis?
A: Sepsis is a life-threatening condition that arises when the body’s response to an infection damages its own tissues and organs.
Q: What is CBG?
A: Corticosteroid-binding globulin is a protein produced in the liver that transports cortisol and appears to have anti-inflammatory properties.
Q: When will this CBG therapy be available to patients?
A: Clinical trials are planned, but a timeline for widespread availability is not yet established.
Q: Is sepsis preventable?
A: While not always preventable, early recognition and treatment of infections can reduce the risk of developing sepsis.
Pro Tip: If you suspect sepsis, seek immediate medical attention. Early intervention is crucial for improving outcomes.
Stay informed about the latest advancements in sepsis research and treatment. Share this article with your network to raise awareness about this critical health issue.
Related reading